低剂量阿司匹林对脑损伤指南分级的创伤性脑损伤结局的影响:一项回顾性队列研究
这项在学术性一级创伤中心开展的回顾性研究纳入1520例创伤性颅内出血并按BIG标准评估的患者,分为BIG 1、BIG 1服用阿司匹林、BIG 2、BIG 3四组,主要终点为神经外科干预与全因院内死亡的复合终点。BIG 1、BIG 1服用阿司匹林、BIG 2、BIG 3的主要结局发生率分别为1%、2.2%、1%、27%,BIG 1服用阿司匹林与BIG 3之间差异显著(p<0.001)。作者据此认为,应将低剂量阿司匹林是否纳入BIG标准重新评估。
要点
- BIG 1服用低剂量阿司匹林患者主要结局(神经外科干预+全因院内死亡)发生率为2.2%,BIG 3为27%,两者差异显著(p<0.001)。
- BIG 1与BIG 2的主要结局发生率均为1%,BIG 3为27%,原文只报告了BIG 1服用阿司匹林与BIG 3的组间比较P值。
- 当前BIG标准将服用抗血小板或抗凝药物的颅内出血患者一律归为BIG 3(最严重类别),不论创伤严重程度。
- 作者认为,应将低剂量阿司匹林是否纳入BIG标准重新评估。
- 研究证据等级为Level IV(治疗/护理管理)。
适用人群与场景
- 因创伤性颅内出血入院并按BIG标准评估的患者。
- 排除标准:BIG状态不确定或主要结局记录缺失者。
- 分组:BIG 1、BIG 2、BIG 3,以及BIG 1服用阿司匹林(具有BIG 1特征且服用低剂量阿司匹林)组。
诊断标准与关键阈值
- 脑损伤指南(BIG)将服用抗血小板或抗凝药物的颅内出血患者归为BIG 3(最严重类别),不论创伤严重程度。
- 本研究中「BIG 1服用阿司匹林」指具有BIG 1特征且服用低剂量阿司匹林的患者。
研究设计与关键结果
- 研究类型:回顾性研究,在学术性一级创伤中心开展。
- 样本量:共1520例患者符合纳入标准。
- 基线:初始格拉斯哥昏迷评分中位数14(IQR 12–15),损伤严重度量表评分中位数17(IQR 10–25),简明损伤定级头颈部评分(AIS Head)中位数3(IQR 3–4)。
- 主要终点为神经外科干预与全因院内死亡的复合终点:BIG 1为1%,BIG 1服用阿司匹林为2.2%,BIG 2为1%,BIG 3为27%;BIG 1服用阿司匹林与BIG 3之间差异显著(p<0.001)。
- 关键次要终点包括颅内出血进展率及ICU与住院无事件天数。
证据类型、等级与局限
- 证据类型:回顾性队列研究;证据等级:Level IV(治疗/护理管理)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,应将低剂量阿司匹林是否纳入BIG标准重新评估;现行BIG将服用抗血小板或抗凝药物的颅内出血患者一律归为BIG 3。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current Brain Injury Guidelines (BIG) characterize patients with intracranial hemorrhage taking antiplatelet or anticoagulant agents as BIG 3 (the most severe category) regardless of trauma severity. This study assessed the risk of in-hospital mortality or need for neurosurgery in patients taking low-dose aspirin who otherwise would be classified as BIG 1.
METHODS: This was a retrospective study at an academic level 1 trauma center. Patients were included if they were admitted with traumatic intracerebral hemorrhage and were evaluated by the BIG criteria. Exclusion criteria included indeterminate BIG status or patients with missing primary outcomes documentation. Patients were categorized as BIG 1, BIG 2, BIG 3, or BIG 1 on aspirin (patients with BIG 1 features taking low-dose aspirin). The primary endpoint was a composite of neurosurgical intervention and all-cause in-hospital mortality. Key secondary endpoints include rate of intracranial hemorrhage progression, and intensive care unit- and hospital-free days.
RESULTS: A total of 1,520 patients met the inclusion criteria. Median initial Glasgow Coma Scale was 14 (interquartile range [IQR], 12-15), Injury Severity Scale score was 17 (IQR, 10-25), and Abbreviated Injury Scale subscore head and neck (AIS Head ) was 3 (IQR, 3-4). The rate of the primary outcome for BIG 1, BIG 1 on aspirin, BIG 2, and BIG 3 was 1%, 2.2%, 1%, and 27%, respectively; the difference between BIG 1 on aspirin and BIG 3 was significant ( p < 0.001).
CONCLUSION: Patients taking low-dose aspirin with otherwise BIG 1-grade injuries experienced mortality and required neurosurgery significantly less often than other patients categorized as BIG 3. Inclusion of low-dose aspirin in the BIG criteria should be reevaluated.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
参考来源
- Webb AJ, Oetken HJ, Plott AJ, et al. The impact of low-dose aspirin in the Brain Injury Guidelines on outcomes in traumatic brain injury: A retrospective cohort study. J Trauma Acute Care Surg. 2022. PMID: 35999660. doi:10.1097/TA.0000000000003772
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。